Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scynexis
Pharma
GSK amends deal with Scynexis amid Brexafemme manufacturing woes
GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme.
Fraiser Kansteiner
Jan 3, 2024 11:44am
Scynexis pulls drug, halts trials on contamination concerns
Sep 25, 2023 12:55pm
GSK strikes antifungal deal as deadly pathogen raises alarm
Mar 30, 2023 11:16am
Scynexis to out license sole commercial med and cut sales team
Oct 20, 2022 3:45pm
Synexis' new data may broaden reach of game-changing Brexafemme
Apr 22, 2022 11:06am
Even during pandemic, FDA approvals remain on a rapid pace
Jul 6, 2021 11:27am
